trial · primary record
Anifrolumab
Lupus Nephritis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 363 |
| Primary completion | 2028-10-04 |
| Primary endpoint | Difference in proportion of participants with CRR (Complete Renal Response) in anifrolumab group compared with placebo group |
| Registry ID | NCT05138133 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:57.060Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05138133
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Anifrolumab · compound